Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_16825 details
Primary information
SALIDSAL_16825
Biomarker nameN1,N12-Diacetylspermidine-d6
Biomarker TypeNA
Sampling MethodThe 359 collected saliva samples, including 57 healthy controls (HCs), 26 patients with benign colorectal tumors (BCTs) and 276 patients with CRC
Collection MethodApproximately 400 µL of unstimulated saliva was collected in a 50 mL polypropylene tube using a polypropylene straw 1.1 cm in diameter to assist the saliva collection.
Analysis MethodCE-MS/MS
Collection SiteSaliva
Disease CategoryCancer
Disease/ConditionColorectal Cancer
Disease SubtypeNA
Fold Change/ ConcentrationNA
Up/DownregulatedNA
ExosomalNA
OrganismHomo sapiens
PMID34233246
Year of Publication2021
Biomarker IDNA
Biomarker CategoryMetabolite
SequenceNA
Title of studyHigh-throughput screening of salivary polyamine markers for discrimination of colorectal cancer by multisegment injection capillary electrophoresis tandem mass spectrometry
Abstract of studyPolyamine metabolites provide pathophysiological information on disease or therapeutic efficacy, yet rapid screening methods for these biomarkers are lacking. Here, we developed high-throughput polyamine metabolite profiling based on multisegment injection capillary electrophoresis triple quadrupole tandem mass spectrometry (MSI-CE-MS/MS), which allows sequential 40-sample injection followed by electrophoretic separation and specific mass detection. To achieve consecutive analysis of polyamine samples, 1 M formic acid was used as the background electrolyte (BGE). The BGE spacer volume had an apparent effect on peak resolution among samples, and 20 nL was selected as the optimal volume. The use of polyamine isotopomers as the internal standard enabled the correction of matrix effects in MS detection. This method is sensitive, selective and quantitative, and its utility was demonstrated by screening polyamines in 359 salivary samples within 360 min, resulting in discrimination of colorectal cancer patients from noncancer controls.